BACKGROUND: Statins, drugs used to treat dyslipidemia, may have anticancer properties. We have evaluated lymphoma risk associated with regular statin use in an international case-control study. METHODS: This case-control study included 2,362 cases of incident B- and T-cell lymphoma from Czech Republic, France, Germany, Ireland, Italy, and Spain and 2,206 hospital or population controls. Information on drug use, diagnosis at admission (for hospital controls), and putative risk factors for lymphoma was collected with personal interviews. Hospital controls admitted for diseases possibly entailing use of statins were excluded from the analysis. RESULTS: The odds ratio for regular statin use was 0.61 (95% confidence interval, 0.45-0.84); all major lymphoma subtypes showed similarly decreased risks. Decreased risks were observed in all centers. Duration of statin use was not associated with a greater reduction in the risk of lymphoma. Use of other lipid lowering drugs, such as fibrates, did not significantly modify the risk of lymphoma (odds ratio, 0.75; 95% confidence interval, 0.44-1.27). CONCLUSION: Statin use was associated with an important reduction in lymphoma risk, adding to the growing evidence of anticancer properties of this group of drugs. These results are reassuring for the increasing number of patients taking statins on a regular basis.
BACKGROUND: Statins, drugs used to treat dyslipidemia, may have anticancer properties. We have evaluated lymphoma risk associated with regular statin use in an international case-control study. METHODS: This case-control study included 2,362 cases of incident B- and T-cell lymphoma from Czech Republic, France, Germany, Ireland, Italy, and Spain and 2,206 hospital or population controls. Information on drug use, diagnosis at admission (for hospital controls), and putative risk factors for lymphoma was collected with personal interviews. Hospital controls admitted for diseases possibly entailing use of statins were excluded from the analysis. RESULTS: The odds ratio for regular statin use was 0.61 (95% confidence interval, 0.45-0.84); all major lymphoma subtypes showed similarly decreased risks. Decreased risks were observed in all centers. Duration of statin use was not associated with a greater reduction in the risk of lymphoma. Use of other lipid lowering drugs, such as fibrates, did not significantly modify the risk of lymphoma (odds ratio, 0.75; 95% confidence interval, 0.44-1.27). CONCLUSION: Statin use was associated with an important reduction in lymphoma risk, adding to the growing evidence of anticancer properties of this group of drugs. These results are reassuring for the increasing number of patients taking statins on a regular basis.
Authors: Chun Chao; Lanfang Xu; Donald I Abrams; William J Towner; Michael A Horberg; Wendy A Leyden; Michael J Silverberg Journal: AIDS Date: 2011-09-10 Impact factor: 4.177
Authors: Mara M Epstein; George Divine; Chun R Chao; Karen E Wells; Heather Spencer Feigelson; Delia Scholes; Douglas Roblin; Marianne Ulcickas Yood; Lawrence S Engel; Andrew Taylor; Joan Fortuny; Laurel A Habel; Christine C Johnson Journal: Int J Cancer Date: 2017-05-15 Impact factor: 7.396
Authors: Ange Wang; Heather A Wakelee; Aaron K Aragaki; Jean Y Tang; Allison W Kurian; JoAnn E Manson; Marcia L Stefanick Journal: Curr Atheroscler Rep Date: 2016-12 Impact factor: 5.113
Authors: Brenda M Birmann; Gabriella Andreotti; Anneclaire J De Roos; Nicola J Camp; Brian C H Chiu; John J Spinelli; Nikolaus Becker; Véronique Benhaim-Luzon; Parveen Bhatti; Paolo Boffetta; Paul Brennan; Elizabeth E Brown; Pierluigi Cocco; Laura Costas; Wendy Cozen; Silvia de Sanjosé; Lenka Foretová; Graham G Giles; Marc Maynadié; Kirsten Moysich; Alexandra Nieters; Anthony Staines; Guido Tricot; Dennis Weisenburger; Yawei Zhang; Dalsu Baris; Mark P Purdue Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-02-21 Impact factor: 4.254
Authors: Nikolaus Becker; Paul Schnitzler; Paolo Boffetta; Paul Brennan; Lenka Foretova; Marc Maynadié; Alexandra Nieters; Anthony Staines; Yolanda Benavente; Pierluigi Cocco; Silvia de Sanjose Journal: J Cancer Res Clin Oncol Date: 2012-07-06 Impact factor: 4.553
Authors: Yukiko Morimoto; Shannon M Conroy; Nicholas J Ollberding; Susanne M Henning; Adrian A Franke; Lynne R Wilkens; Marc T Goodman; Brenda Y Hernandez; Loïc Le Marchand; Brian E Henderson; Laurence N Kolonel; Gertraud Maskarinec Journal: Cancer Causes Control Date: 2012-08-21 Impact factor: 2.506
Authors: Nikolaus Becker; Joan Fortuny; Tomas Alvaro; Alexandra Nieters; Marc Maynadié; Lenka Foretova; Anthony Staines; Paul Brennan; Paolo Boffetta; Pier Luigi Cocco; Silvia de Sanjose Journal: J Cancer Res Clin Oncol Date: 2009-02-11 Impact factor: 4.553